Clarkston recently partnered with a client that is a biopharmaceutical company developing, manufacturing, and marketing regenerative biologics utilizing human placental ...

Clarkston recently partnered with a biopharmaceutical company on their FDA inspection readiness for business systems project. This company develops, manufactures, ...

On April 11, I attended the NC Tech Talk Live panel discussion on Cybersecurity Metrics in the very impressive WeWork ...

Medicine is changing. Advances in platform technologies and personalized treatments are fundamentally changing the way drugs are discovered, manufactured, and ...

For an emerging business to mature from a growth stage to a global success, the company’s organizational structure, process discipline, ...

For the seventh year in a row, Clarkston Consulting attended the Association for Accessible Medicines (AAM) Annual Meeting.  Many thanks ...

The internet of labs (IoL) or super labs of the future will not just be one centralized lab, but a ...

To answer questions about the impact of new US tax legislation, repatriation of outsourced services, and tax-efficient supply chains, I ...

On February 28th in his address to Congress, President Trump urged legislators to bring down drug prices ‘immediately.’  And, the ...

Last week, we were fortunate to attend this year’s GPhA Annual Meeting in Orlando. As always, the event offered opportunities ...

The FDA's Plan to Transform & Evolve Through Data

Every year patents for branded drugs continue to expire and with each expiration, the generics market expands ever larger. As the market ...